FDA Launches App for Health Care Professionals

FDAThe U.S. Food and Drug Administration announced the global launch of CURE ID, an internet-based repository that will allow the clinical community to report their experiences treating difficult-to-treat infectious diseases with novel uses of existing FDA-approved drugs through a website, a smartphone or other mobile device. The platform enables the crowdsourcing of medical information from health care providers to guide potentially life-saving interventions and facilitate the development of new drugs for neglected diseases. The repository is a collaboration between the FDA and the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH).

"The CURE ID application focuses on drugs for infectious diseases lacking adequate treatments, including neglected tropical diseases, emerging infectious threats and infections caused by antimicrobial-resistant organisms. When health care professionals directly input their clinical cases into the app, CURE ID allows these real-world experiences to be organized and analyzed much faster, making it easier to spot promising new uses for existing drugs," said Amy Abernethy, M.D., Ph.D., FDA Principal Deputy Commissioner. "Our hope is that this app will serve as a connector among major treatment centers, academics, private practitioners, government facilities and other health care professionals from around the world and ultimately get treatments to patients faster."

The repository captures clinical outcomes when drugs are used for new indications, in new populations, in new doses or in new combinations. Health care professionals generally may choose to prescribe or use a legally marketed human drug or medical device for an unapproved or uncleared use when they judge that the unapproved use is medically appropriate for an individual patient. The systematic collection of real-world experience in the app will help identify drug candidates for additional study, encourage further drug development, and may serve as a resource for practitioners making individual patient treatment decisions in the absence of established safe and effective options. Repurposing approved drugs for new clinical indications can potentially offer an efficient drug-development pathway for treatments of diseases and conditions that have few or no therapeutic options.

"The potential importance of new therapeutic opportunities from repurposing drugs can’t be understated," said NCATS Director Christopher P. Austin, M.D. "The CURE ID platform exemplifies how collaborative efforts can spark innovations that benefit patients. This new platform harnesses the power of crowdsourcing to help gather medical observations in the field and help identify potentially effective treatments for diseases."

The app works by collecting a simple case report form from caregivers about their experience using an approved product for an unapproved use. Health care professionals can browse from a collection of cases that have already been documented, including successful and unsuccessful treatments, in addition to viewing relevant clinical trials and those open to enrollment at clinicaltrials.gov. App users can also participate in a treatment discussion forum where they can engage with fellow providers globally. The FDA plans to reach out to health care providers in various disciplines, including infectious and tropical diseases, to encourage them to use the app.

The full launch of the app follows the release of several pilot versions after an initial innovation award was received from the U.S. Department of Health & Human Services IDEA Lab in April 2015. During the pilots, extensive user-testing was conducted in India (2015 and 2017) and South Africa (2016). Additional feedback was also collected from users in the U.S., Europe and Peru. The updated app that launched today includes the addition of a newsfeed, an improved search feature with data from 325 different infectious diseases and syndromes to choose from, and the inclusion of nearly 1,500 initial cases from clinicians and the published literature and over 18,000 clinical trials.

To download and use the CURE ID application, visit https://cure.ncats.io or download "CURE ID" from the App or Play Store.

About FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Most Popular Now

AI Helps Physicians Better Assess the Ef…

In a small but multi-institutional study, an artificial intelligence (AI)-based system improved providers' assessments of whether patients with bladder cancer had complete response to chemotherapy before a radical cystectomy (bladder...

Smartwatches and Fitness Bands Reveal In…

A new digital health study by researchers at Scripps Research shows how data from wearable sensors, such as smartwatches and fitness bands, can track a person’s physiological response to the...

AI may Detect Earliest Signs of Pancreat…

An artificial intelligence (AI) tool developed by Cedars-Sinai investigators accurately predicted who would develop pancreatic cancer based on what their CT scan images looked like years prior to being diagnosed...

Open Call U4H-2022-PJ2: Call for Proposa…

The Ukraine crisis has an unprecedented impact on the mental health of the displaced people in the EU coming from Ukraine. The conflict and experiences of people in war zones...

AI Reduces Miss Rate of Precancerous Pol…

Artificial intelligence reduced by twofold the rate at which precancerous polyps were missed in colorectal cancer screening, reported a team of international researchers led by Mayo Clinic. The study is...

Medical Valley EMN & Volitan Global …

The two healthcare innovation experts Medical Valley EMN and Volitan Global strengthen their existing inbound- and outbound activities through a strategic partnership. The aim is to offer companies access to...

DMEA - Connecting Digital Health Opens w…

26 - 28 April 2022, Berlin, Germany. What plans does the new federal government have concerning the digital transformation of the healthcare sector? What are the initial experiences of doctors regarding...

AI can Predict Probability of COVID-19 v…

Testing shortages, long waits for results, and an over-taxed health care system have made headlines throughout the COVID-19 pandemic. These issues can be further exacerbated in small or rural communities...

Using AI to Detect Cancer from Patient D…

A new way of using artificial intelligence to predict cancer from patient data without putting personal information at risk has been developed by a team including University of Leeds medical...

Oulu University Hospital Expands Partner…

Siemens Healthineers and Oulu University Hospital in Finland have entered a strategic partnership for the next ten years, adding to an existing radiotherapy collaboration to jointly expand and modernize the...

Positive Conclusion to DMEA - Connecting…

26 - 28 April 2022, Berlin, Germany. After three days DMEA, Europe's leading digital health event, came to a successful conclusion - with around 11,000 visitors, more than 500 exhibitors and...

AI-Enabled ECGs may Identify Patients at…

Atrial fibrillation, the most common cardiac rhythm abnormality, has been linked to one-third of ischemic strokes, the most common type of stroke. But atrial fibrillation is underdiagnosed, partly because many...